三氧化二砷与急性早幼粒细胞白血病：临床与生物学特性

Arsenic trioxide and acute promyelocytic leukemia: clinical and biological.

作者信息

Chen Z, Zhao W L, Shen Z X, Li J M, Chen S J, Zhu J, Lallemand-Breittenbach V, Zhou J, Guillemin M C, Vitoux D, de Thé H

机构信息

Shanghai Institute of Hematology, Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong University, 197 Rui Jin Road II, 200025 Shanghai, People's Republic of China.

出版信息

Curr Top Microbiol Immunol. 2007;313:129-44. doi: 10.1007/978-3-540-34594-7_8.

DOI:10.1007/978-3-540-34594-7_8

PMID:17217042

Abstract

Arsenic has recently been identified as an effective drug in the treatment of newly diagnosed and relapsed acute promyelocytic leukemia. Indeed, arsenic trioxide combined with all-trans retinoic acid shows a synergistic effect. Mechanistically, arsenic targets the key leukemogenic protein PML-RARalpha, setting up a new example of molecular target-based cancer therapy.

摘要

最近，砷已被确定为治疗新诊断和复发的急性早幼粒细胞白血病的有效药物。事实上，三氧化二砷与全反式维甲酸联合使用显示出协同效应。从机制上讲，砷靶向关键的致白血病蛋白PML-RARα，树立了基于分子靶点的癌症治疗的新典范。